Abiopharma

🔍 Lindgardt Zhenya (Executive)

Company: SERA PROGNOSTICS, INC. (SERA)

Report Date: 2026-03-10

Detailed Transactions and Holdings:

• Sold 22,639 shares of Class A Common Stock at $1.9 per share (Direct)
  Date: 2026-03-10 | Code: S | equity_swap_involved: false | shares_owned_after: 741,287.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,973 shares of Class A Common Stock at $2.04 per share (Direct)
  Date: 2026-03-11 | Code: S | equity_swap_involved: false | shares_owned_after: 738,314.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person.
• F2: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $1.77 to $2.36, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade.
• F3: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $1.90 to $2.30, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade.